Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Thyroid Carcinoma, Anaplastic 2Respiratory Tract Neoplasms 2Colorectal Neoplasms 2Thyroid Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma 1Liposarcoma 1Advanced Non-small Cell Lung Cancer (NSCLC) 1Advanced Cancer 1

Interventions

Cyclophosphamide 444Rituximab 401Etoposide 224Vincristine 215Doxorubicin 201Filgrastim 200Prednisone 176Cytarabine 159Radiotherapy 152fludarabine phosphate 147Methotrexate 137Peripheral Blood Stem Cell Transplantation 129Melphalan 127fludarabine 115Busulfan 99Dexamethasone 93Tacrolimus 75Carmustine 74Granulocyte Colony-Stimulating Factor 73Mycophenolic Acid 71Gemcitabine 66Bortezomib 65Antilymphocyte Serum 65Whole-Body Irradiation 62Cyclosporine 62Bendamustine Hydrochloride 62Lenalidomide 60Ifosfamide 58sargramostim 51Methylprednisolone 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lymphoma × efatutazone × Clear all
NCT01504490 2017-02-14

Phase I Study of CS-7017 and Bexarotene

Georgetown University

Phase 1 Terminated
9 enrolled
LymphoidPlasma cell

Lymphoma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡